Chiara Riganti

发表

Overcoming the lack of kinetic information in biochemical reactions networks

Marco Beccuti, Francesca Cordero, Laura Follia, 2017, PERV.

Dealing with indetermination in biochemical networks

Marco Beccuti, Francesca Cordero, Laura Follia, 2016, VALUETOOLS.

Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma

Shana O. Kelley, Silvia Deaglio, Ilaria Roato, 2016, Molecular Cancer Therapeutics.

An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo

Ali Ertürk, Hagen Scherb, Chiara Riganti, 2018, International journal of cancer.

Recent Advances in Medicinal Chemistry

Fabio Polticelli, Ann Nowé, Hendrik Fuchs, 2017 .

Activation of Nuclear Factor-κB Pathway by Simvastatin and RhoA Silencing Increases Doxorubicin Cytotoxicity in Human Colon Cancer HT29 Cells

Amalia Bosia, Dario Ghigo, Elisabetta Aldieri, 2008, Molecular Pharmacology.

High aspect ratio materials: role of surface chemistry vs. length in the historical “long and short amosite asbestos fibers”

Gianmario Martra, Bice Fubini, Dario Ghigo, 2010, Inhalation toxicology.

PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy

Chiara Riganti, Paolo Provero, P. Provero, 2017, Molecular Cancer.

The role of C/EBP-β LIP in multidrug resistance.

Chiara Riganti, J. Kopecka, C. Riganti, 2015, Journal of the National Cancer Institute.

Iron-loaded synthetic chrysotile: a new model solid for studying the role of iron in asbestos toxicity.

Elisabetta Foresti, Isidoro Giorgio Lesci, Norberto Roveri, 2007, Chemical research in toxicology.

RhoA Silencing Reverts the Resistance to Doxorubicin in Human Colon Cancer Cells

Amalia Bosia, Dario Ghigo, Elisabetta Aldieri, 2008, Molecular Cancer Research.